Profile

        Dr. Wu earned her medical degree from Fudan University (formerly Shanghai First Medical College) in 1984, her master degree in Industrial Hygiene and Occupational Diseases from Zhejiang University (formerly Zhejiang Medical University) in 1987, and following a postdoctoral fellowship in INERIS, France from 1990 to 1991, she earned her Ph.D. from The University of Texas School of Public Health in 1994. From 1995 to 2019, he served in the University of Texas MD Anderson Cancer Center that ranked the first in the American Cancer Hospitals from Tenure-Track Assistant Professor to Tenured Professor, and served as an Adjunct Professor at the University of Texas School of Public Health. In 2004, he was awarded as tenured professor. In 2006, he was named endowed Ashbel Smith Professorship. In 2008, she was named endowed Betty B. Marcus Chair in Cancer Prevention until 2019. From 2010 to 2019, she served as Leader for the Premalignant Genome Atlas program, Director for the Center for Translational and Public Health Genomics including a Blood Specimen Research Resource and Personalized Risk Prediction Program. From 2011 to 2019, he served as Director of the Patient History Database. From 2011 to 2015, she served as Chair for the Department of Epidemiology and Leader of the Department of Epidemiology Program.

Dr. Wu’s multifaceted research program bridges the fields of epidemiology, laboratory, clinical, and computational research.  The overall theme of her research program is to use highly innovative and integrative research strategies to discover novel modifiable risk factors, uncover molecular signatures, and create robust prediction models for risk stratification across the cancer continuum. She has established substantial research infrastructure including MD Anderson Cancer Patients and Survivors Cohort, the Premalignant Lesion Patient Cohort, the Long-term Survivorship Cohort, Blood Specimen Research Resource, Personalized Risk Prediction Program, and several large case control and clinical outcome studies. Furthermore, she developed successful productive collaboration with MJ Health Research Foundation in Taiwan on a large prospective cohort of over half a million individuals. She had led one of the largest laboratory at MD Anderson Cancer Center.

Dr. Wu has been one of the most funded researchers in MD Anderson Cancer Center and the entire US cancer epidemiology field. She is a highly productive cancer epidemiologist with over 545 publications, including Nature Genetics, Lancet, Lancet Oncology, JAMA, JNCI, JCO, Gut, NEJM, Science, etc. Her provocative studies showed that moderate exercise reduced mortality and extended life expectancy, which led to her proposed MPOWER measures to reduce burden of physical inactivity. She identified novel cancer predisposition loci, discovered mutations with driver patterns and created a 20-gene panel to distinguish colorectal adenoma from adenocarcinoma. She constructed several powerful risk prediction models for cancer screening, early detection, prognosis, and toxicity. Dr. Wu is the mentor for many junior faculty, post-graduate students, postdocs and clinicians. She has won the Best Boss and Best Mentor Awards many times. She has trained 50 graduate students, 33 postdoctoral fellows, and 43 clinicians and visiting scholars. Among them, 61 people received various academic honors and awards.

Dr. Wu has received many awards, including MD Anderson Cancer Center’s Faculty Scholar Award, UT Ashbel Smith Professorship, the Margaret and James A. Elkins Jr. Faculty Achievement Award in Cancer Prevention, the Julie and Ben Rogers Award for Excellence in Research, Betty B. Marcus Chair in Cancer Prevention, senior fellow of MD Anderson Research Trust, the Robert Chamberlain Distinguished Mentor Award, Houston’s 50 most influential women, and Leading Mentor in Cancer Prevention. She has served on committees for the US National Cancer Institute, the European Research Council, the Cancer Research United Kingdom, China National Molecular Translational Center, and many others.

Below are some details:

l  Devoted significant efforts to establish big data and building research infrastructures for The University of Texas MD Anderson Cancer Center:

-    Initiated and established Blood Specimen Research Resource (BSRR), ~110,000 subjects enrolled

-    Transitioned Patient History Data Base (PHDB) from paper to electronic PHDB and implemented it in 24 clinical care centers, ~550,000 subjects enrolled

-    Initiated and established MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC), ~220,000 subjects enrolled

-    Initiated and established full collaboration with Taiwan Health Management Foundation on MJ Cohort,  ~1,000,000 subjects, median follow-up 14 years

-    Established One of the largest case-control and clinical outcome studies for bladder, esophageal, and

     renal cancers in the United States and one of the largest clinical outcome studies for lung cancer

-    Initiated and established Premalignant Lesion Patient Cohorts, e.g., colorectal adenoma, oral  premalignant lesions

-    Established Long-term Survivorship Cohort

-    Initiated Pediatric Patient Cohort

-    Established Comprehensive Molecular Epidemiology Laboratory

-    Initiated and established Premalignant Genome Atlas program

-    Initiated and established Center for Translational and Public Health Genomics and extended Personalized Risk Prediction Program

-    She established policies for governance of these resources, including the creation of biospecimen and data access committees. These committees, with cross-institutional membership, have approved many project requests from investigators in departments across MD Anderson.  She has made the best usage of these resources, e.g., These resources helped obtain extramural funding totaling $39.5 million in recent years.  Particularly noteworthy were the recent four large NCI R01 NGS projects (bringing $21 million to MD Anderson) led by junior investigators, these were the direct benefits of these large resources. 

l  Has a stellar record of extramural funding, ranked first in grants across all departments at MD Anderson according to the institutional academic profile in 2014, played a critical role in many of the Institutional program projects such as lung Cancer SPORE, Bladder Cancer SPORE, Head and Neck Cancer SPORE, Prostate Cancer SPORE, and Oral Premalignant Lesions P01 program. Below are some examples of her grants:

-    PI of four SPORE projects which were renewed multiple times (lung, bladder, head and neck cancer, and prostate cancer)

-    PI of a NCI R01 PQ on link between obesity and renal cell carcinoma

-    PI of a CPRIT project on lung cancer

-    PI of a NCI R01 PQ on liver cancer

-    Co-PI of a CPRIT project on prostate cancer 

-    PI of a colorectal cancer moonshot project

-    Co-I with significant role in 4 large sequencing grants, 2 U01, a R01, and a moonshot project

-    MD Anderson site PI for a NCI R01 on lymphoma

-    MD Anderson site PI for a NCI R01 on breast cancer 

-    MD Anderson site PI for a NCI R01 on cervical cancer

-    MD Anderson site PI for a NCI R01 on barretts’ esophagus

-    PI of a R01 of esophageal adenocarcinoma study 

-    PI of a U01 of bladder cancer genome-wide association study 

-    PI of a R01 of renal cell carcinoma (RCC) case control study

-    PI of a P01 project on oral premalignant lesions

-    PI of a R01 of bladder cancer study, renewed multiple times (completed, renewed in SPORE)

-    Multiple PI of a U19 on lung cancer

-    PI of a lung moonshot project, a prostate moonshot project, a colorectal cancer moonshot project

-    Co-leader of a head and neck cancer SPORE program

-    PI of a R01 on lung cancer pharmacogenetics

-    PI of a R01 on twin study

l  Published over 545 peer-reviewed papers and book chapters including top prestigious journals such as New England Journal of Medicine,  Nature, Science, Nature Genetics, Lancet, Lancet Oncology, Journal of American Medical Association, British Medical Journal, Journal of national Cancer nstitute, Journal of Clinical Oncology, Clinical Cancer Research, etc.      

l  A consummate collaborator, with the top team score at the Institution.

l  Serving on many national and international grant review and other important committees for Nationl Cancer Institute, American Association for Cancer Research, European      Research Council, Cancer Research United Kingdom, China National Molecular Translational Center, Poland, Spain, Italy, Holland, Singapore, France, and more.

Positions and Honors

Positions

1990-1991 Postdoctoral Fellow, National Laboratory of Industrial Environment and Risk Analysis, Division of Occupational Health, Verneuil-en-Halatte, France

1995-2000 Tenure-Track Assistant Professor, Department of Epidemiology, The University of Texas MD Anderson Cancer Center (MD Anderson), Houston, TX

2000-2004 Tenured Associate Professor, Department of Epidemiology, MD Anderson, Houston, TX

2004-2019 Tenured Professor, Department of Epidemiology, MD Anderson, Houston, TX

2009-2019 Leader, Premalignant Genome Atlas Program, Duncan Family Institute for Cancer Prevention and Risk Assessment, MD Anderson, Houston, TX

2010-2019 Director, Center for Translational and Public Health Genomics, MD Anderson, Houston, TX

2011-2015 Leader, Cancer Center Support Grant Epidemiology Program, MD Anderson, Houston, TX

2011-2015 Chair, Department of Epidemiology, MD Anderson, Houston, TX

2011-2019t     Executive Sponsor, Institutional Patient History Database, MD Anderson, Houston, TX

Honors and Awards

2016 -- Leading Mentor in Cancer Prevention, Division of Cancer Prevention and Population Science

2015 -- Outstanding Contribution Award, International Interdisciplinary Colon/Rectal Cancer Conference

2014 -- Houston's 50 Most Influential Women

2012，2011，2010，2009，2008，2007, Certificate for Exceptional Leadership and Support as a Mentor at The University of Texas MD Anderson Cancer Center

2011 -- Robert M. Chamberlain Distinguished Mentor Award, MD Anderson Cancer Center

2010 -- Leading Mentor in Cancer Prevention, Division of Cancer Prevention and Population Science

2008 -- The Margaret and James A. Elkins, Jr. Faculty Achievement Award in Cancer Prevention, The University of Texas MD Anderson Cancer Center

2008 -- Julie and Ben Rogers Award for Excellence, MD Anderson Cancer Center, 2008

2008-2013 -- Senior Fellow of the MD Anderson Research Trust, MD Anderson Cancer Center

2008-2019 -- Betty B. Marcus Chair in Cancer Prevention, MD Anderson Cancer Center,

2007 -- Best Boss Award Finalist, The University of Texas MD Anderson Cancer Center

2006 -- Ashbel Smith Professorship, The University of Texas

2002 -- Faculty Scholar Award, MD Anderson Cancer Center

Impact

l  Built largest and innovative biobanks and patient databases and shared with investigators across the Institution

l  Trained many young scientists, who received 61 awards

l  Published provocative studies using the Taiwan MJ Cohort population showing that 15 minutes moderate exercise reduced 14% of risk of all-cause mortality and extends life expectancy for three years (Lancet, 2011, 2012, 2013) and proposed MPOWER measures to reduce burden of physical inactivity (Lancet, 2012)

l  Identified novel cancer predisposition loci for several cancers including lung, bladder, kidney, ovarian, and testicular cancer and lymphoma and published in world top journals (Nature Genetics, 2008, 2009, 2010, 2011, 2012, 2013, and 2014; Lancet Oncology, 2010; Nature Communication, 2015, 2016; Human Molecular Genetics, 2011, 2012, 2013, 2014, 2016; and American Journal of Human Genetics, 2014) and novel genetic loci for lung cancer survival (Journal of National Cancer Institute, 2011, Cancer Research, 2013, 2014)

l  Constructed powerful personalized risk prediction models using multi-dimensional data integration for bladder cancer (Journal of National Cancer Institute, 2007), liver cancer (Journal of National Cancer Institute, 2012), lung cancer (Scientific Reporter, 2016), breast cancer recurrence (Journal of National Cancer Institute, 2017), radiation toxicity (Clinical Pharmacology & Therapeutics, 2014), and lung cancer recurrence (Clinical Pharmacology & Therapeutics, 2017)

l  Discovered a set of genes with distinctive mutation patterns between adenoma and CRC and potential biomarkers for early detection, which may function as drivers of progression. Created a 20-gene mutation panel that best discriminated adenoma and CRC with a prediction accuracy of 0.93 (Gut, 2017)

l  Discovered that chronic diseases contributed to more than one-fifth of cancer incidence risk and more than one-third of cancer mortality risk which is as important as five major lifestyle factors combined. Recognition of this overlooked cancer risk may change current cancer prevention strategies and motivate better control of chronic diseases. Fortunately, physical activity may reduce nearly 40% the cancer risk associated with chronic diseases. Individuals with highest chronic disease risk score shortened their life span for almost 16 years (British Medical Journal, 2018)

Selected from over 545 manuscripts and book chapters:

Established a Series Big Data/ Cohorts

l  Wu X, Tsai SP, Tsao CK, Chiu ML, Tsai MK, Lu PJ, Lee JH, Chen CH, Wen C, Chang SS, Hsu CY, Wen CP. Cohort Profile: The Taiwan MJ Cohort: half a million Chinese with repeated health surveillance data. Int J Epidemiol. e-Pub 2/2017. PMID: 28204597.

l  Chow WH, Chrisman M, R Daniel C, Ye Y, Gomez H, Dong Q, Anderson CE, Chang S, Strom S, Zhao H, Wu X. Cohort Profile: The Mexican American Mano a Mano Cohort. Int J Epidemiol. e-pub Mar 8, 2015. PMID: 25747868.

l  Wu X, Hildebrandt MA, Ye Y, Chow WH, Gu J, Cunningham S, Zhao H, Hawk ET, Wagar E, Rodriguez A, Hamilton SR. Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC). Int J Epidemiol. e-Pub 12/2015. PMID: 26686840.

Discovered Novel Modifiable Risk Factors

l  Tu H, Wen CP, Tsai SP, Chow WH, Wen C, Ye Y, Zhao H, Tsai MK, Huang M, Dinney CP, Tsao CK, Wu X. Cancer risk of chronic diseases and disease markers: a prospective cohort study of 405,878 individuals. British Medical Journal, 360:k134. doi: 10.1136/bmj.k134, 2018 Jan 31, PMID: 29386192.

l  Tu H, Dinney CP, Ye Y, Grossman HB, Lerner S, Wu X. Is folic acid safe? An evidence-based study in non-muscle-invasive bladder cancer patients. Am J Clin Nutr. 107(2):208-216, 2018 Feb 1. PMID: 29529165.

l  Melkonian SC, Daniel CR, Ye Y, Pierzynski JA, Roth JA, Wu X. Glycemic Index, Glycemic Load, and Lung Cancer Risk in Non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev. 25(3):532-9, 2016. PMID:26944871.

l  Melkonian SC, Daniel CR, Hildebrandt MA, Tannir NM, Ye Y, Chow WH, Wood CG, Wu X. Joint association of genome-Wide association study-identified susceptibility loci and dietary patterns in risk of renal cell carcinoma among non-Hispanic whites. Am J Epidemiol. 180(5): 499-507, 2014 . PMCID: PMC4143080.

l  Shu X, Lin J, Wood CG, Tannir NM, Wu X. Energy Balance, Polymorphisms in the mTOR Pathway, and Renal Cell Carcinoma Risk. J Natl Cancer Inst 105(6):424-32, 3/2013. PMCID: PMC3601952.

l  Wen CP, Tsai MK, Wai JP, Wu X. Promoting increased physical activity and reduced inactivity - Authors' reply. Lancet 381(9861):114-5, 1/2013. PMID: 23312751.

l  Wen CP, Wai JP, Tsai MK, Yang YC, Cheng TY, Lee MC, Chan HT, Tsao CK, Tsai SP, Wu X. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet 378(9798):1244-53, 10/2011. PMID: 21846575.

Uncovered Novel Molecular Signatures

l  Lin SH, Raju GS, Huff C, Ye Y, Gu J, Chen JS, Hildebrandt MAT, Liang H, Menter DG, Morris J, Hawk E, Stroehlein JR, Futreal A, Kopetz S, Mishra L, Wu X. The somatic mutation landscape of premalignant colorectal adenoma. Gut, 67(7):1299-1305, 2018 Jul. PMID: 28607096.

l  Tu H, Sun L, Dong X, Gong Y, Xu Q, Jing J, Bostick RM, Wu X, Yuan Y. A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study. Am J Gastroenterol 112(5):704-715, 5/2017. PMID: 28323271.

l  Scelo G, Purdue MP, Brown KM, Johansson M, Wang Z, Eckel-Passow JE, Ye Y, Hofmann JN, Choi J, Foll M, Gaborieau V, Machiela MJ, Colli LM, Li P, Sampson JN, Abedi-Ardekani B, Besse C, Blanche H, Boland A, Burdette L, Chabrier A, Durand G, Le Calvez-Kelm F, Prokhortchouk E, Robinot N, Skryabin KG, Wozniak MB, Yeager M, Basta-Jovanovic G, Dzamic Z, Foretova L, Holcatova I, Janout V, Mates D, Mukeriya A, Rascu S, Zaridze D, Bencko V, Cybulski C, Fabianova E, Jinga V, Lissowska J, Lubinski J, Navratilova M, Rudnai P, Szeszenia-Dabrowska N, Benhamou S, Cancel-Tassin G, Cussenot O, Baglietto L, Boeing H, Khaw KT, Weiderpass E, Ljungberg B, Sitaram RT, Bruinsma F, Jordan SJ, Severi G, Winship I, Hveem K, Vatten LJ, Fletcher T, Koppova K, Larsson SC, Wolk A, Banks RE, Selby PJ, Easton DF, Pharoah P, Andreotti G, Freeman LEB, Koutros S, Albanes D, Männistö S, Weinstein S, Clark PE, Edwards TL, Lipworth L, Gapstur SM, Stevens VL, Carol H, Freedman ML, Pomerantz MM, Cho E, Kraft P, Preston MA, Wilson KM, Michael Gaziano J, Sesso HD, Black A, Freedman ND, Huang WY, Anema JG, Kahnoski RJ, Lane BR, Noyes SL, Petillo D, Teh BT, Peters U, White E, Anderson GL, Johnson L, Luo J, Buring J, Lee IM, Chow WH, Moore LE, Wood C, Eisen T, Henrion M, Larkin J, Barman P, Leibovich BC, Choueiri TK, Mark Lathrop G, Rothman N, Deleuze JF, McKay JD, Parker AS, Wu X (co-last author), Houlston RS, Brennan P, Chanock SJ. Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nat Commun, 2017 Jun 9;8:15724. doi: 10.1038/ncomms15724. PMID: 28598434.

l  Berndt SI, Camp NJ, Skibola CF, Vijai J, Wang Z, Gu J, Nieters A, Kelly RS, Smedby KE, Monnereau A, Cozen W, Cox A, Wang SS, Lan Q, Teras LR, Machado M, Yeager M, Brooks-Wilson AR, Hartge P, Purdue MP, Birmann BM, Vajdic CM, Cocco P, Zhang Y, Giles GG, Zeleniuch-Jacquotte A, Lawrence C, Montalvan R, Burdett L, Hutchinson A, Ye Y, Call TG, Shanafelt TD, Novak AJ, Kay NE, Liebow M, Cunningham JM, Allmer C, Hjalgrim H, Adami HO, Melbye M, Glimelius B, Chang ET, Glenn M, Curtin K, Cannon-Albright LA, Diver WR, Link BK, Weiner GJ, Conde L, Bracci PM, Riby J, Arnett DK, Zhi D, Leach JM, Holly EA, Jackson RD, Tinker LF, Benavente Y, Sala N, Casabonne D, Becker N, Boffetta P, Brennan P, Foretova L, Maynadie M, McKay J, Staines A, Chaffee KG, Achenbach SJ, Vachon CM, Goldin LR, Strom SS, Leis JF, Weinberg JB, Caporaso NE, Norman AD, De Roos AJ, Morton LM, Severson RK, Riboli E, Vineis P, Kaaks R, Masala G, Weiderpass E, Chirlaque MD, Vermeulen RC, Travis RC, Southey MC, Milne RL, Albanes D, Virtamo J, Weinstein S, Clavel J, Zheng T, Holford TR, Villano DJ, Maria A, Spinelli JJ, Gascoyne RD, Connors JM, Bertrand KA, Giovannucci E, Kraft P, Kricker A, Turner J, Ennas MG, Ferri GM, Miligi L, Liang L, Ma B, Huang J, Crouch S, Park JH, Chatterjee N, North KE, Snowden JA, Wright J, Fraumeni JF, Offit K, Wu X (co-last author), de Sanjose S, Cerhan JR, Chanock SJ, Rothman N, Slager SL. Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. Nat Commun 7:10933, 3/2016. PMCID: PMC4786871.

l  Mendoza-Pérez J, Gu J, Herrera LA, Tannir NM, Matin SF, Karam JA, Huang M, Chang DW, Wood CG, Wu X. Genomic DNA hypomethylation and risk of renal cell carcinoma: A case-control study. Clin Cancer Res 22(8):2074-82, 4/2016. PMCID: PMC4834236.

l  Wen CP, Zhang F, Liang D, Wen C, Gu J, Skinner H, Chow WH, Ye Y, Pu X, Hildebrandt MA, Huang M, Chen CH, Hsiung CA, Tsai MK, Tsao CK, Lippman SM, Wu X. The ability of bilirubin in identifying smokers with higher risk of lung cancer: a large cohort study in conjunction with global metabolomic profiling. Clin Cancer Res 21(1):193-200, 1/2015. PMCID: PMC4286447.

l  Cerhan JR, Berndt SI, Vijai J, Ghesquières H, McKay J, Wang SS, Wang Z, Yeager M, Conde L, de Bakker PI, Nieters A, Cox D, Burdett L, Monnereau A, Flowers CR, De Roos AJ, Brooks-Wilson AR, Lan Q, Severi G, Melbye M, Gu J, Jackson RD, Kane E, Teras LR, Purdue MP, Vajdic CM, Spinelli JJ, Giles GG, Albanes D, Kelly RS, Zucca M, Bertrand KA, Zeleniuch-Jacquotte A, Lawrence C, Hutchinson A, Zhi D, Habermann TM, Link BK, Novak AJ, Dogan A, Asmann YW, Liebow M, Thompson CA, Ansell SM, Witzig TE, Weiner GJ, Veron AS, Zelenika D, Tilly H, Haioun C, Molina TJ, Hjalgrim H, Glimelius B, Adami HO, Bracci PM, Riby J, Smith MT, Holly EA, Cozen W, Hartge P, Morton LM, Severson RK, Tinker LF, North KE, Becker N, Benavente Y, Boffetta P, Brennan P, Foretova L, Maynadie M, Staines A, Lightfoot T, Crouch S, Smith A, Roman E, Diver WR, Offit K, Zelenetz A, Klein RJ, Villano DJ, Zheng T, Zhang Y, Holford TR, Kricker A, Turner J, Southey MC, Clavel J, Virtamo J, Weinstein S, Riboli E, Vineis P, Kaaks R, Trichopoulos D, Vermeulen RC, Boeing H, Tjonneland A, Angelucci E, Di Lollo S, Rais M, Birmann BM, Laden F, Giovannucci E, Kraft P, Huang J, Ma B, Ye Y, Chiu BC, Sampson J, Liang L, Park JH, Chung CC, Weisenburger DD, Chatterjee N, Fraumeni JF, Slager SL, Wu X（co-last author）, de Sanjose S, Smedby KE, Salles G, Skibola CF, Rothman N, Chanock SJ. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet 46(11):1233-8, 11/2014. PMCID: PMC4213349.

l  Pu X, Ye Y, Spitz MR, Wang L, Gu J, Lippman SM, Hildebrandt MA, Hong WK, Minna JD, Roth JA, Yang P, Wu X. Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study. Clin Cancer Res 18(21):5983-91, 11/2012. PMCID: PMC3640870.

l  Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 103(10):817-25, 5/2011. PMCID: PMC3096796.

l  Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X (co-first author), Figueroa JD, Real FX, Van Den Berg D, Matullo G, Baris D, Thun M, Kiemeney LA, Vineis P, De Vivo I, Albanes D, Purdue MP, Rafnar T, Hildebrandt MA, Kiltie AE, Cussenot O, Golka K, Kumar R, Taylor JA, Mayordomo JI, Jacobs KB, Kogevinas M, Hutchinson A, Wang Z, Fu YP, Prokunina-Olsson L, Burdett L, Yeager M, Wheeler W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Grubb R, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Cortessis VK, Gago-Dominguez M, Pike MC, Stern MC, Yuan JM, Hunter DJ, McGrath M, Dinney CP, Czerniak B, Chen M, Yang H, Vermeulen SH, Aben KK, Witjes JA, Makkinje RR, Sulem P, Besenbacher S, Stefansson K, Riboli E, Brennan P, Panico S, Navarro C, Allen NE, Bueno-de-Mesquita HB, Trichopoulos D, Caporaso N, Landi MT, Canzian F, Ljungberg B, Tjonneland A, Clavel-Chapelon F, Bishop DT, Teo MT, Knowles MA, Guarrera S, Polidoro S, Ricceri F, Sacerdote C, Allione A, Cancel-Tassin G, Selinski S, Hengstler JG, Dietrich H, Fletcher T, Rudnai P, Gurzau E, Koppova K, Bolick SC, Godfrey A, Xu Z, Sanz-Velez JI, D García-Prats M, Sanchez M, Valdivia G, Porru S, Benhamou S, Hoover RN, Fraumeni JF, Silverman DT, Chanock SJ. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 42(11):978-84, 11/2010. PMCID: PMC3049891.

l  Li Y, Sheu CC, Ye Y, de Andrade M, Wang L, Chang SC, Aubry MC, Aakre JA, Allen MS, Chen F, Cunningham JM, Deschamps C, Jiang R, Lin J, Marks RS, Pankratz VS, Su L, Li Y, Sun Z, Tang H, Vasmatzis G, Harris CC, Spitz MR, Jen J, Wang R, Zhang ZF, Christiani DC, Wu X (co-last author), Yang P. Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 11(4):321-30, 4/2010. PMCID: PMC2945218.

l  Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, Seminara D, Yoshida T, Saeki N, Andrew AS, Dinney CP, Czerniak B, Zhang ZF, Kiltie AE, Bishop DT, Vineis P, Porru S, Buntinx F, Kellen E, Zeegers MP, Kumar R, Rudnai P, Gurzau E, Koppova K, Mayordomo JI, Sanchez M, Saez B, Lindblom A, de Verdier P, Steineck G, Mills GB, Schned A, Guarrera S, Polidoro S, Chang SC, Lin J, Chang DW, Hale KS, Majewski T, Grossman HB, Thorlacius S, Thorsteinsdottir U, Aben KK, Witjes JA, Stefansson K, Amos CI, Karagas MR, Gu J. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 41(9):991-5, 9/2009. PMCID: PMC3313685.

l  Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X. Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway are Associated with Clinical Outcomes in Esophageal Cancer Patients Treated with Chemoradiotherapy. J Clin Oncol 27(6):857-71, 2/2009. e-Pub 1/2009. PMCID: PMC2738430.

l  Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, Sullivan K, Matakidou A, Wang Y, Mills G, Doheny K, Tsai YY, Chen WV, Shete S, Spitz MR, Houlston RS. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40(5):616-22, 5/2008. e-Pub 4/2008. PMCID: PMC2713680.

l  Wu X, Gu J, Wu TT, Swisher SG, Liao Z, Correa AM, Liu J, Etzel CJ, Amos CI, Huang M, Chiang SS, Milas L, Hittelman WN, Ajani JA. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24(23): 3789-98，2006. PMID: 16785472.

l  Rebbeck TR, Spitz M, Wu X. Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet 5(8):589-97, 2004. PMID: 15266341.

l  Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, Luo S, Hong WK, Spitz MR. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 95(16):1211-8, 2003. PMID: 12928346.

Created Robust Prediction Models for Risk Stratification across the Cancer Continuum

l  Wu X, Ye Y, Barcenas CH, Chow WH, Meng QH, Chavez-MacGregor M, Hildebrandt MA, Zhao H, Gu X, Deng Y, Wagar E, Esteva FJ, Tripathy D, Hortobagyi GN. Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. J Natl Cancer Inst 109(7), 7/2017. PMID: 28376179.

l  Wu X, Wen CP, Ye Y, Tsai M, Wen C, Roth JA, Pu X, Chow WH, Huff C, Cunningham S, Huang M, Wu S, Tsao CK, Gu J, Lippman SM. Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan. Sci Rep 6:36482, 11/2016. PMCID: PMC5090352.

l  Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Etzel C, Huang M, Hsu CY, Ye Y, Mishra L, Hawk E, Wu X. Hepatocellular Carcinoma Risk Prediction Model for the General Population: The Predictive Power of Transaminases. J Natl Cancer Inst 104(20):1599-611, 10/2012. PMCID: PMC3692381.

l  Wu X, Lin J, Grossman HB, Huang M, Gu J, Etzel CJ, Amos CI, Dinney CP, Spitz MR. Projecting Individualized Probabilities of Developing Bladder Cancer in Caucasians. J Clin Oncol 25(31):4974-81, 11/2007. PMID: 17971596.